Yasutaka Watanabe
Saitama, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 28 publications
Immune-related gene expression profiling and alectinib efficacy for patients with ALK-Rearranged non-small cell lung cancer: exploratory analysis of a prospective observational study.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: November 05, 2025
Biomarkers of nivolumab benefit in resectable non-small cell lung cancer.
Journal: Nature
Published: November 04, 2025
Cemiplimab in Japanese patients with advanced non-small cell lung cancer.
Journal: Japanese journal of clinical oncology
Published: July 11, 2025
Clinical outcomes with perioperative nivolumab by nodal status in patients with stage III resectable NSCLC: phase 3 CheckMate 77T exploratory analysis.
Journal: Nature cancer
Published: January 13, 2025
Randomized Phase III Study of EGFR Tyrosine Kinase Inhibitor and Intercalated Platinum-Doublet Chemotherapy for Non-Small Cell Lung Cancer Harboring EGFR Mutation.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: October 23, 2024
Corrigendum to "A phase II study (WJOG12819L) to assess the efficacy of osimertinib in patients with EGFR mutation-positive NSCLC in whom systemic disease (T790M-negative) progressed after treatment with first- or second-generation EGFR TKI and platinum-based chemotherapy" [Lung Cancer 177 (2023) 44-50].
Journal: Lung cancer (Amsterdam, Netherlands)
Published: June 18, 2024
Perioperative Nivolumab in Resectable Lung Cancer.
Journal: The New England journal of medicine
Published: May 15, 2024
A phase 2 study of mobocertinib as first-line treatment in Japanese patients with non-small cell lung cancer harboring EGFR exon 20 insertion mutations.
Journal: International journal of clinical oncology
Published: April 24, 2024
Last Updated: 09/26/2026